SCHEMBL4047289

SCHEMBL4047289

CCCC(NC(=O)c1ccc(-c2cccs2)cc1)C(=O)N1CCC2C1C(=O)CN2C(=O)Cc1cccnc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.43
HDAC1 Q13547 4/20 0.39
HPGDS O60760 1/20 0.39
DRD2 P14416 4/20 0.38
DRD4 P21917 4/20 0.38
HTR2A P28223 2/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
GPR132 Q9UNW8 3/20 0.37
ACE P12821 1/20 0.36
DPP4 P27487 1/20 0.36
PREP P48147 1/20 0.36
PTAFR P25105 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040750 0.92 CTSK (0.52) CTSKHDAC1HPGDSCHRNB2CHRNA7
SCHEMBL4041957 0.91 CTSK (0.42) CTSKHDAC1HPGDSDRD2DRD4
SCHEMBL4040781 0.91 CTSK (0.42) CTSKHDAC1HPGDSDRD2DRD4
SCHEMBL4045236 0.89 CTSK (0.47) CTSKGPR132ACEPREPPTAFR
SCHEMBL4039803 0.88 CTSK (0.49) CTSKGPR132ACE
SCHEMBL3947909 0.87 CTSK (0.39) CTSKHDAC1HPGDSDRD2DRD4
SCHEMBL4037490 0.87 CTSK (0.48) CTSKGPR132ACEPTAFR
SCHEMBL4037811 0.87 CTSK (0.57) CTSKGPR132ACEPREP
SCHEMBL4039388 0.87 CTSK (0.45) CTSKGPR132PTAFRCHRNB2CHRNA7
SCHEMBL4039065 0.87 CTSK (0.57) CTSKGPR132ACEPREPPTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885HDAC1 261/4885HPGDS 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.